ASCO GI 2021 | POLO: maintenance olaparib in BRCA1/2 metastatic pancreatic cancer

Mohamed E. Salem, MD, Levine Cancer Institute, Charlotte, NC, discusses the updated survival results of the POLO study (NCT02184195), a Phase III trial evaluating the efficacy of olaparib as maintenance therapy in patients who had a germline BRCA1 or BRCA2 mutation and metastatic pancreatic cancer. The findings of this updated overall survival analysis demonstrated no benefit of using olaparib maintenance, despite progression-free survival showing improvements with the use of PARP inhibitors. Dr Salem continues to discuss the treatment implications of this study, and the next stages in the use of olaparib in patients with pancreatic cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).